The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
BackgroundPatients with extensive-stage small-cell lung cancer (ES-SCLC) have high recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment of ES-SCLC.Method...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.894835/full |
_version_ | 1811266327046782976 |
---|---|
author | Hao-Ran Zheng Hao-Ran Zheng Ai-Min Jiang Huan Gao Na Liu Xiao-Qiang Zheng Xiao Fu Zhi-Ping Ruan Tao Tian Xuan Liang Yu Yao |
author_facet | Hao-Ran Zheng Hao-Ran Zheng Ai-Min Jiang Huan Gao Na Liu Xiao-Qiang Zheng Xiao Fu Zhi-Ping Ruan Tao Tian Xuan Liang Yu Yao |
author_sort | Hao-Ran Zheng |
collection | DOAJ |
description | BackgroundPatients with extensive-stage small-cell lung cancer (ES-SCLC) have high recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment of ES-SCLC.MethodsPathologically confirmed ES-SCLC patients receiving anlotinib plus platinum-etoposide chemotherapy as the first-line treatment were enrolled in this retrospective study. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions. The Cox regression analyses were employed to investigate the independent prognostic factors for OS and PFS of these individuals.ResultsIn total, 58 patients were included in this study. The median PFS was 6.0 months [95% confidence interval (CI): 3.5-8.5], and the median OS was 10.5 months (95%CI 8.7-12.3). Thirty-four patients achieved partial response (PR), 18 patients achieved stable disease (SD), and 6 patients achieved progressive disease (PD). The ORR and DCR were 58.6% and 89.6%. The main treatment-related adverse reactions were generally tolerated. Myelosuppression (44.8%) was the most common adverse reaction, followed by hypertension (41.4%), fatigue (34.5%), gastrointestinal reaction (32.7%), and hand-foot syndrome (24.1%). Multivariate analysis showed that post-medication hand-foot syndrome [PFS 8.5 vs. 5.5 months, Hazards Ratio (HR)=0.23, 95%CI 0.07-0.72, P =0.012] was the independent predictor of PFS, and hypertension (OS 15.9 vs. 8.3 months, HR=0.18, 95%CI 0.05-0.58, P =0.005) was the independent predictor of OS.ConclusionAnlotinib combined with platinum-etoposide chemotherapy as the first-line treatment for ES-SCLC appears to be effective and well-tolerated in the real-world. Well-designed large-scale prospective studies are urgently needed in the future to verify our findings. |
first_indexed | 2024-04-12T20:40:50Z |
format | Article |
id | doaj.art-bcffe294e47c490fa68083e505bce920 |
institution | Directory Open Access Journal |
issn | 2234-943X |
language | English |
last_indexed | 2024-04-12T20:40:50Z |
publishDate | 2022-09-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Oncology |
spelling | doaj.art-bcffe294e47c490fa68083e505bce9202022-12-22T03:17:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.894835894835The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world studyHao-Ran Zheng0Hao-Ran Zheng1Ai-Min Jiang2Huan Gao3Na Liu4Xiao-Qiang Zheng5Xiao Fu6Zhi-Ping Ruan7Tao Tian8Xuan Liang9Yu Yao10Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, Xi’an No.3 Hospital, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaBackgroundPatients with extensive-stage small-cell lung cancer (ES-SCLC) have high recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment of ES-SCLC.MethodsPathologically confirmed ES-SCLC patients receiving anlotinib plus platinum-etoposide chemotherapy as the first-line treatment were enrolled in this retrospective study. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions. The Cox regression analyses were employed to investigate the independent prognostic factors for OS and PFS of these individuals.ResultsIn total, 58 patients were included in this study. The median PFS was 6.0 months [95% confidence interval (CI): 3.5-8.5], and the median OS was 10.5 months (95%CI 8.7-12.3). Thirty-four patients achieved partial response (PR), 18 patients achieved stable disease (SD), and 6 patients achieved progressive disease (PD). The ORR and DCR were 58.6% and 89.6%. The main treatment-related adverse reactions were generally tolerated. Myelosuppression (44.8%) was the most common adverse reaction, followed by hypertension (41.4%), fatigue (34.5%), gastrointestinal reaction (32.7%), and hand-foot syndrome (24.1%). Multivariate analysis showed that post-medication hand-foot syndrome [PFS 8.5 vs. 5.5 months, Hazards Ratio (HR)=0.23, 95%CI 0.07-0.72, P =0.012] was the independent predictor of PFS, and hypertension (OS 15.9 vs. 8.3 months, HR=0.18, 95%CI 0.05-0.58, P =0.005) was the independent predictor of OS.ConclusionAnlotinib combined with platinum-etoposide chemotherapy as the first-line treatment for ES-SCLC appears to be effective and well-tolerated in the real-world. Well-designed large-scale prospective studies are urgently needed in the future to verify our findings.https://www.frontiersin.org/articles/10.3389/fonc.2022.894835/fullsmall cell lung canceranlotinibchemotherapyreal-world dataefficacysafety |
spellingShingle | Hao-Ran Zheng Hao-Ran Zheng Ai-Min Jiang Huan Gao Na Liu Xiao-Qiang Zheng Xiao Fu Zhi-Ping Ruan Tao Tian Xuan Liang Yu Yao The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study Frontiers in Oncology small cell lung cancer anlotinib chemotherapy real-world data efficacy safety |
title | The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study |
title_full | The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study |
title_fullStr | The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study |
title_full_unstemmed | The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study |
title_short | The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study |
title_sort | efficacy and safety of anlotinib combined with platinum etoposide chemotherapy as first line treatment for extensive stage small cell lung cancer a chinese multicenter real world study |
topic | small cell lung cancer anlotinib chemotherapy real-world data efficacy safety |
url | https://www.frontiersin.org/articles/10.3389/fonc.2022.894835/full |
work_keys_str_mv | AT haoranzheng theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT haoranzheng theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT aiminjiang theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT huangao theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT naliu theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT xiaoqiangzheng theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT xiaofu theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT zhipingruan theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT taotian theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT xuanliang theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT yuyao theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT haoranzheng efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT haoranzheng efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT aiminjiang efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT huangao efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT naliu efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT xiaoqiangzheng efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT xiaofu efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT zhipingruan efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT taotian efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT xuanliang efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy AT yuyao efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy |